-

ZIVO Bioscience to Present at The Microcap Conference 2025

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.

Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company’s recent developments, growth strategy, and investment opportunities.

Event: The Microcap Conference 2025
Location: Studio 1, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 2:30 PM Eastern Time

Investors interested in meeting with management can register for the conference here.

About ZIVO Bioscience

Zivo Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

Contacts

ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com

Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com

Industry:

Zivo Bioscience, Inc.

OTCQB:ZIVO
Release Versions
English

Contacts

ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com

Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com

More News From Zivo Bioscience, Inc.

ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass

TROY, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the signing of a manufacturing agreement with Cyanotech Corporation to grow, cultivate and process ZIVO's proprietary algal biomass for its Zivolife™ product line. ZIVO is advancing Zivolife™ toward commercial applications acros...

ZIVO Bioscience Provides Special Letter to Shareholders

TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. (“ZIVO” or the “Company”): we intend to deregister the Company’s securities with the Securities and Exchange Commission and cease public reporting. This letter...

ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses

TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am pleased to provide you with this important update on the significant progress by ZIVO Bioscience and a review of our exciting future direc...
Back to Newsroom